DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 4 May 2026 · Closes today
In plain terms
The US Defense Health Agency funds research to develop therapeutic treatments for amyotrophic lateral sclerosis, from preclinical validation through FDA-enabling studies. US-based organisations of any type may apply if they have lead compounds with proof-of-concept efficacy data, but the deadline of 30 September 2026 has now passed.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the…
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- academia_research
- private_company
- government
- social_enterprise
- individual
- other
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"